Antibodies to infliximab are associated with lower infliximab levels and increased likelihood of surgery in pediatric IBD
| Autor: | Julia Bender Stern, Linda Heiner, Naamah L. Zitomersky, Scott Hauenstein, Michael C. Butler, Lori A. Ashworth, Sharat Singh, Benjamin J. Atkinson, Kerri Ann Fournier, Emil Chuang, Paul Mitchell, Athos Bousvaros |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
musculoskeletal diseases
Adult Male medicine.medical_specialty Combination therapy Adolescent Inflammatory bowel disease Antibodies Article Young Adult Crohn Disease Interquartile range medicine Immunology and Allergy Humans skin and connective tissue diseases Child Crohn's disease business.industry Gastroenterology Case-control study Infant Newborn Antibodies Monoclonal Infant medicine.disease Prognosis Ulcerative colitis Infliximab Surgery Cross-Sectional Studies Case-Control Studies Child Preschool Methotrexate Colitis Ulcerative Female business medicine.drug Follow-Up Studies |
| Zdroj: | Inflammatory bowel diseases. 21(2) |
| ISSN: | 1536-4844 |
| Popis: | BACKGROUND Adult studies suggest antibodies to infliximab (ATI) correlate with loss of response in inflammatory bowel disease but pediatric data are limited. METHODS We conducted a cross-sectional study of trough infliximab levels and ATI in 134 pediatric and young adult patients receiving infliximab. At the time serum was obtained demographics, disease phenotype, duration of infliximab therapy, use of combination therapy (methotrexate or 6-mercaptopurine with infliximab), and surgery were recorded. RESULTS Assays were performed on 134 subjects currently receiving infliximab (85 male; mean age, 17.3 ± 4.3 years; 114 Crohn's disease and 20 ulcerative colitis). Infliximab use ranged from 12 days to 12 years: median 2.0 (interquartile range [1.1-4.3]) years. Twenty-seven of 134 (20%) patients had ATI ≥5 U/mL. Of patients with ATI ≥5 U/mL, 59% had infliximab levels |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|